Pantop%2525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a substituted benzimidazole proton pump inhibitor (PPI). It suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. It is available as oral delayed-release tablets, oral suspension, and intravenous injection. ## Primary Indications * Short-term treatment (up to 8 weeks) of erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Prophylaxis of stress-induced upper gastrointestinal bleeding (off-label/institutional protocol). ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. * **Pathological Hypersecretory Conditions:** Starting dose 40 mg twice daily. Doses up to 240 mg daily have been used, but titration is guided by clinical response and acid output measurements. * **IV Bolus:** 40 mg administered over 15 minutes. Infusion: 40 mg over 15–30 minutes or continuous infusion at 8 mg/hr (following 80 mg bolus for GI bleed protocols). ## Pediatric Dosing * **Erosive Esophagitis (5 years and older):** * 15 kg to <40 kg: 20 mg once daily for up to 8 weeks. * 40 kg or greater: 40 mg once daily for up to 8 weeks. * *Note:* Pediatric dosing for stress ulcer prophylaxis is not standardized and depends strictly on institutional protocols. ## Dose Adjustments * **Hepatic Impairment:** Reduce dose in severe hepatic impairment (Child-Pugh C). Maximum dose of 20 mg daily or 40 mg every other day. * **Renal Impairment:** No dosage adjustment necessary. * **Geriatric:** No dosage adjustment necessary. ## Contraindications * Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole). * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, flatulence. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, and increased risk of fractures (with chronic high-dose use). ## Key Drug Interactions * **pH-Dependent Drugs:** May decrease absorption of drugs requiring acidic gastric pH (e.g., atazanavir, nelfinavir, itraconazole, ketoconazole). * **Methotrexate:** PPIs may increase serum levels of methotrexate, especially in high-dose therapy. * **Clopidogrel:** Potential for reduced antiplatelet effect of clopidogrel due to CYP2C19 inhibition; clinical significance remains debated. ## Monitoring * Monitor for signs of *C. difficile* infection (unrelenting diarrhea). * Long-term use: Monitor magnesium levels (if on therapy >1 year), B12 levels, and bone mineral density if risk factors for osteoporosis exist. * Monitor hepatic function in patients with severe liver disease. ## Clinical Pearls * **Administration:** Tablets should be swallowed whole; do not crush or chew. Suspension can be administered via NG tube (check institutional compatibility guidelines). * **Timing:** Administer 30 minutes before a meal (typically breakfast) for optimal efficacy. * **IV Access:** IV pantoprazole is compatible with NS, LR, and D5W. Always use an in-line filter (1.2 micron) for parenteral administration. * **Deprescribing:** Utilize "tapering" strategies for long-term users to avoid rebound acid hypersecretion. *** **Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and interaction profiles can change. Always verify current prescribing information using local institutional protocols, electronic health record databases (e.g., Lexicomp, Micromedex), and the FDA-approved product label before prescribing or administering medication.